Company news

Revolution Medicines, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Revolution Medicines to Participate in November 2026 Investor Conferences

October 27, 2026

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

October 23, 2026

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

October 21, 2026

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

October 20, 2026

Revolution Medicines’ RASONQUE™ (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer

October 15, 2026

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

October 5, 2026

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

September 14, 2026

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

September 2, 2026

U.S. FDA Approves Revolution Medicines' RASONQUE (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

August 27, 2026

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

August 26, 2026

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

August 11, 2026

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

August 5, 2026

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

July 29, 2026

Revolution Medicines New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

July 23, 2026

Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

July 22, 2026

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

July 7, 2026

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

July 1, 2026

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

June 23, 2026

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

June 23, 2026

Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.

June 21, 2026

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

May 31, 2026

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

May 21, 2026

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

May 6, 2026

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

May 6, 2026

Statement on FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer

May 1, 2026

Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

April 29, 2026

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

April 21, 2026

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

April 21, 2026

Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting

April 19, 2026

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 17, 2026

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

April 14, 2026

Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes

April 12, 2026

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer

April 1, 2026

Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

March 16, 2026

Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

February 25, 2026

Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference

February 24, 2026

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

February 23, 2026

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

February 18, 2026

Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

February 4, 2026

Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor

January 28, 2026

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib

January 7, 2026

Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

December 17, 2025

Delphia Therapeutics Appoints Leading Cancer Expert Steve Kelsey, M.D., to Board of Directors

December 9, 2025

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

November 4, 2025

Revolution Medicines to Participate in November 2025 Investor Conferences

November 3, 2025

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

October 28, 2025

Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

October 26, 2025

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

October 21, 2025

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

October 15, 2025

Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.